The global Vaccines Market, valued at US$59.52 billion in 2024, stood at US$50.46 billion in 2025 and is projected to advance at a ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them. Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals ...

Coupled with headwinds in China, Merck is also seeing lower demand for Gardasil in Japan. Sales are expected to remain weak in Japan in the second half of 2025. Our estimates for Gardasil sales ...

Real-world study data showed that the monoclonal antibody nirsevimab was highly effective at preventing severe respiratory ...

ACOG released updated clinical guidance on vaccination for COVID-19, respiratory syncytial virus and influenza during ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Merck said it expects the actions under the restructuring program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection ...

Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person’s hand holding a bottle of pharmaceuticals.

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...